Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Heart Transplant Rejection: Pipeline Review (H1 2018) Featuring Astellas Pharma, Heat Biologics, Noxxon Pharma, and TxCell - ResearchAndMarkets.com

October 19, 2018

DUBLIN--(BUSINESS WIRE)--Oct 19, 2018--The “Heart Transplant Rejection - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection (Immunology). The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Heart Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Heart Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Heart Transplant Rejection (Immunology)

Companies Featured

Astellas Pharma Inc. Heat Biologics Inc. Noxxon Pharma AG TxCell SA

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c7qdk6/heart_transplant?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181019005209/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs,Immunosuppressive Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/19/2018 06:06 AM/DISC: 10/19/2018 06:06 AM


All contents © copyright 2019 The Associated Press. All rights reserved.